Nacuity Pharmaceuticals

About Nacuity Pharmaceuticals

Nacuity Pharmaceuticals, a clinical-stage biopharmaceutical firm established in 2016, is focused on developing therapies to treat diseases caused by oxidative stress. The company was founded in Fort Worth, Texas, by a team of veterans from Alcon Laboratories with deep experience in ophthalmic product development and commercialization. Halden Conner, a co-founder who also serves as Chairman and CEO, previously sat on the Alcon Laboratories board and co-founded Protom International. The company's scientific foundation is built upon the research of Dr. Peter Campochiaro of the Wilmer Eye Institute, which centers on the role of oxidative stress in the retina.

Nacuity's business model revolves around the development and clinical advancement of prescription therapies that target oxidative tissue damage, a key factor in many blinding eye diseases and other chronic conditions. The company has raised a total of $30.9 million over four funding rounds, including a notable $16.5 million Series B round in June 2022 led by the Foundation Fighting Blindness and its venture arm, the RD Fund. This financial backing supports the progression of its clinical trials through the proof-of-concept stage. By concentrating on orphan and rare pediatric diseases, Nacuity aims for a time- and capital-efficient development process that could lead to priority review vouchers from the FDA.

The company's lead product candidate is NPI-001, a proprietary oral tablet formulation of N-acetylcysteine amide (NACA) designed to mitigate oxidative stress by boosting the body's production of glutathione, a powerful antioxidant. This gene-agnostic approach has the potential to treat a wide range of patients irrespective of the specific genetic mutation causing their disease. In a Phase 1/2 clinical trial for Retinitis Pigmentosa (RP) associated with Usher syndrome, NPI-001 demonstrated the ability to slow photoreceptor loss by over 50% compared to a placebo over two years. This success has led to the FDA granting NPI-001 both Orphan Drug and Fast Track designations, and more recently, Breakthrough Therapy Designation. A confirmatory trial is planned for 2026. Other clinical programs include NPI-002, an intravitreal implant to slow cataract progression, and treatments for nephropathic cystinosis and a rare neurological disease.